Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is MELOXICAM USP, with a corresponding US DMF Number 17148.
Remarkably, this DMF maintains an Active status since its submission on February 06, 2004, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of September 06, 2017, and payment made on August 21, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II